Several studies have reported that the presence of BAP1 mutations or the loss of expression in prostate cancer tissues leads to worse clinical outcomes, while the loss of BAP1 function has been shown to enhance AR activity, potentially contributing to the aggressive behavior of prostate cancer cells [17,18]. This evidence concerns the gene AR and prostate cancer.